Tags

Type your tag names separated by a space and hit enter

HbA1c, fasting plasma glucose and the prediction of diabetes: Inter99, AusDiab and D.E.S.I.R.
Diabetes Res Clin Pract. 2012 Jun; 96(3):392-9.DR

Abstract

INTRODUCTION

With diabetes defined by HbA1c≥6.5% and/or FPG≥7.0mmol/l and/or diabetes treatment, we investigated HbA1c and fasting plasma glucose (FPG) thresholds/change-points above which the incidence of diabetes increases.

METHODS

Data are Danish (Inter99), Australian (AusDiab) and French (D.E.S.I.R.), with respectively 4930, 6012 and 3784 non-diabetic participants.

RESULTS

Diabetes incidences at 5 years for Inter99 and AusDiab and at 6 years for D.E.S.I.R. were 2.3%, 3.1% and 2.4% respectively and incidences increased with baseline HbA1c and FPG. As HbA1c distributions differed between cohorts, HbA1c was standardized on D.E.S.I.R. data. Change-points where diabetes incidence increased were identified for HbA1c (%) after standardization: 5.1 (4.9-5.6) (Inter99), 5.4 (5.1-5.6) (AusDiab), 5.3 (5.1-5.7) (D.E.S.I.R.); for FPG change-points (mmol/l) were 5.1 (…-6.1) (Inter99), 5.5 (5.2-5.8) (AusDiab), no change-point for D.E.S.I.R. Using current diabetes risk criteria HbA1c≥5.7% and/or FPG≥5.6mmol/l to screen for diabetes provided high sensitivity (over 89%) and positive predictive values: 4.3%, 6.9%, and 5.9% respectively.

CONCLUSIONS

HbA1c and FPG change-points predicting incident diabetes did not always exist, differed across studies, when available were generally lower than current criteria with wide confidence intervals. Using jointly HbA1c≥5.7% and/or FPG≥5.6mmol/l as a criterion for the risk of incident diabetes is appropriate.

Authors+Show Affiliations

Université Paris Sud 11, UMRS 1018, Villejuif, France. soraya.soulimane@inserm.frNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21741107

Citation

Soulimane, Soraya, et al. "HbA1c, Fasting Plasma Glucose and the Prediction of Diabetes: Inter99, AusDiab and D.E.S.I.R." Diabetes Research and Clinical Practice, vol. 96, no. 3, 2012, pp. 392-9.
Soulimane S, Simon D, Shaw J, et al. HbA1c, fasting plasma glucose and the prediction of diabetes: Inter99, AusDiab and D.E.S.I.R. Diabetes Res Clin Pract. 2012;96(3):392-9.
Soulimane, S., Simon, D., Shaw, J., Witte, D., Zimmet, P., Vol, S., Borch-Johnsen, K., Magliano, D., Vistisen, D., & Balkau, B. (2012). HbA1c, fasting plasma glucose and the prediction of diabetes: Inter99, AusDiab and D.E.S.I.R. Diabetes Research and Clinical Practice, 96(3), 392-9. https://doi.org/10.1016/j.diabres.2011.06.003
Soulimane S, et al. HbA1c, Fasting Plasma Glucose and the Prediction of Diabetes: Inter99, AusDiab and D.E.S.I.R. Diabetes Res Clin Pract. 2012;96(3):392-9. PubMed PMID: 21741107.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - HbA1c, fasting plasma glucose and the prediction of diabetes: Inter99, AusDiab and D.E.S.I.R. AU - Soulimane,Soraya, AU - Simon,Dominique, AU - Shaw,Jonathan, AU - Witte,Daniel, AU - Zimmet,Paul, AU - Vol,Sylviane, AU - Borch-Johnsen,Knut, AU - Magliano,Dianna, AU - Vistisen,Dorte, AU - Balkau,Beverley, Y1 - 2011/07/07/ PY - 2011/01/14/received PY - 2011/05/23/revised PY - 2011/06/02/accepted PY - 2011/7/12/entrez PY - 2011/7/12/pubmed PY - 2012/10/20/medline SP - 392 EP - 9 JF - Diabetes research and clinical practice JO - Diabetes Res Clin Pract VL - 96 IS - 3 N2 - INTRODUCTION: With diabetes defined by HbA1c≥6.5% and/or FPG≥7.0mmol/l and/or diabetes treatment, we investigated HbA1c and fasting plasma glucose (FPG) thresholds/change-points above which the incidence of diabetes increases. METHODS: Data are Danish (Inter99), Australian (AusDiab) and French (D.E.S.I.R.), with respectively 4930, 6012 and 3784 non-diabetic participants. RESULTS: Diabetes incidences at 5 years for Inter99 and AusDiab and at 6 years for D.E.S.I.R. were 2.3%, 3.1% and 2.4% respectively and incidences increased with baseline HbA1c and FPG. As HbA1c distributions differed between cohorts, HbA1c was standardized on D.E.S.I.R. data. Change-points where diabetes incidence increased were identified for HbA1c (%) after standardization: 5.1 (4.9-5.6) (Inter99), 5.4 (5.1-5.6) (AusDiab), 5.3 (5.1-5.7) (D.E.S.I.R.); for FPG change-points (mmol/l) were 5.1 (…-6.1) (Inter99), 5.5 (5.2-5.8) (AusDiab), no change-point for D.E.S.I.R. Using current diabetes risk criteria HbA1c≥5.7% and/or FPG≥5.6mmol/l to screen for diabetes provided high sensitivity (over 89%) and positive predictive values: 4.3%, 6.9%, and 5.9% respectively. CONCLUSIONS: HbA1c and FPG change-points predicting incident diabetes did not always exist, differed across studies, when available were generally lower than current criteria with wide confidence intervals. Using jointly HbA1c≥5.7% and/or FPG≥5.6mmol/l as a criterion for the risk of incident diabetes is appropriate. SN - 1872-8227 UR - https://www.unboundmedicine.com/medline/citation/21741107/HbA1c_fasting_plasma_glucose_and_the_prediction_of_diabetes:_Inter99_AusDiab_and_D_E_S_I_R_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0168-8227(11)00301-9 DB - PRIME DP - Unbound Medicine ER -